Pages that link to "Q41720190"
Jump to navigation
Jump to search
The following pages link to Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group (Q41720190):
Displaying 50 items.
- Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients (Q24245456) (← links)
- Disparities in kidney transplant outcomes: a review (Q33636818) (← links)
- Risk for posttransplant Diabetes mellitus with current immunosuppressive medications (Q33684389) (← links)
- Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients (Q33806753) (← links)
- Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens (Q33806770) (← links)
- Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases (Q33838866) (← links)
- Immunosuppression for lung transplantation (Q33996931) (← links)
- Donor race does not predict graft failure after liver transplantation (Q34007521) (← links)
- Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients (Q34017371) (← links)
- The metabolic effects of cyclosporin and tacrolimus (Q34045311) (← links)
- Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy (Q34069142) (← links)
- Drug-nutrient interactions in transplant recipients (Q34239257) (← links)
- Tailoring immunosuppressive therapy based on donor and recipient risk factors (Q34264180) (← links)
- Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation (Q34332261) (← links)
- Risk factors and incidence of posttransplant diabetes mellitus (Q34332586) (← links)
- Impact of immunosuppressive regimes on posttransplant diabetes mellitus (Q34332598) (← links)
- Strategies for risk reduction and management of posttransplant diabetes mellitus (Q34332602) (← links)
- Tailoring immunosuppressive therapy for renal transplant recipients (Q34459657) (← links)
- Immunosuppressive therapy and post-transplantation diarrhea (Q34485488) (← links)
- Sirolimus: a comprehensive review (Q34515537) (← links)
- Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients (Q34580586) (← links)
- Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin (Q34598372) (← links)
- The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies (Q34604689) (← links)
- The impact of ethnicity on the natural history of autoimmune hepatitis (Q34664271) (← links)
- Cardiovascular toxicities of immunosuppressive agents (Q34976738) (← links)
- Persistent racial disparities in survival after heart transplantation (Q35073670) (← links)
- Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects (Q35162452) (← links)
- Calcineurin inhibitors in renal transplantation: what is the best option? (Q35187355) (← links)
- Pharmacokinetic Differences Corroborate Observed Low Tacrolimus Dosage in Native American Renal Transplant Patients (Q35415535) (← links)
- New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis (Q35691924) (← links)
- Pharmacology of calcineurin antagonists (Q35710811) (← links)
- Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials (Q35918055) (← links)
- African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients (Q38636398) (← links)
- Pharmacokinetic principles of immunosuppressive drugs. (Q36006086) (← links)
- Guidelines for the treatment and management of new-onset diabetes after transplantation (Q36118632) (← links)
- Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes (Q36541052) (← links)
- Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy (Q36544981) (← links)
- Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium (Q36630081) (← links)
- The burden of new-onset diabetes mellitus after transplantation (Q36652095) (← links)
- Drug insight: maintenance immunosuppression in kidney transplant recipients (Q36662474) (← links)
- Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial (Q36732942) (← links)
- Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation (Q36761340) (← links)
- Tacrolimus in the treatment of idiopathic nephrotic syndrome. (Q36861628) (← links)
- Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus (Q36908443) (← links)
- Similar outcomes among black and white renal allograft recipients (Q37042165) (← links)
- Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients (Q37157896) (← links)
- Ethnic advantages in kidney transplant outcomes: the Hispanic Paradox at work? (Q37290783) (← links)
- New-onset diabetes mellitus after solid organ transplantation (Q37336859) (← links)
- Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials (Q37442389) (← links)
- African American kidney transplantation survival: the ability of immunosuppression to balance the inherent pre- and post-transplant risk factors (Q37605772) (← links)